Novo Nordisk A/S (NYSE:NVO) Trading Up 0.5%

Shares of Novo Nordisk A/S (NYSE:NVO) were up 0.5% during trading on Friday . The company traded as high as $124.54 and last traded at $123.39. Approximately 1,419,238 shares were traded during mid-day trading, a decline of 71% from the average daily volume of 4,830,868 shares. The stock had previously closed at $122.75.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on NVO shares. UBS Group began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating for the company. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Thursday. Finally, BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price for the company. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Trading Up 0.2 %

The stock has a market capitalization of $552.15 billion, a P/E ratio of 45.62, a price-to-earnings-growth ratio of 2.08 and a beta of 0.41. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The stock’s fifty day moving average price is $126.36 and its two-hundred day moving average price is $110.50.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. Equities research analysts forecast that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were issued a $0.664 dividend. This represents a dividend yield of 0.9%. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S’s payout ratio is presently 49.17%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Roundview Capital LLC increased its position in Novo Nordisk A/S by 0.6% during the 1st quarter. Roundview Capital LLC now owns 18,803 shares of the company’s stock valued at $2,088,000 after purchasing an additional 106 shares during the period. BlackRock Inc. increased its position in Novo Nordisk A/S by 45.4% during the 1st quarter. BlackRock Inc. now owns 5,035,879 shares of the company’s stock valued at $559,235,000 after purchasing an additional 1,571,747 shares during the period. Dimensional Fund Advisors LP increased its position in Novo Nordisk A/S by 0.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 739,585 shares of the company’s stock valued at $82,131,000 after purchasing an additional 6,903 shares during the period. Blair William & Co. IL increased its position in Novo Nordisk A/S by 12.7% during the 1st quarter. Blair William & Co. IL now owns 19,466 shares of the company’s stock valued at $2,136,000 after purchasing an additional 2,194 shares during the period. Finally, Sei Investments Co. boosted its holdings in shares of Novo Nordisk A/S by 17.5% during the 1st quarter. Sei Investments Co. now owns 107,175 shares of the company’s stock valued at $11,913,000 after buying an additional 15,996 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.